Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc/ US4622221004 /
IONS
|
2024-05-01 10:00:00 PM
|
Chg.
+1.7500
|
Volume |
Bid1:55:09 AM |
Ask1:55:09 AM |
High |
Low |
|
43.0100USD
|
+4.24%
|
1.07 mill.
Turnover: 28.99 mill. |
41.9100Bid Size: 100 |
44.3400Ask Size: 100 |
43.6000 |
41.0500 |
Business description
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics in the United States. Its portfolio includes SPINRAZA, TEGSEDI, and WAYLIVRA for various genetic disorders. Additionally, it has multiple phase 3 studies underway for treatments addressing conditions like amyotrophic lateral sclerosis and cardiovascular disease. Headquarters: Carlsbad, California. Founded: 1989. Collaborations: Biogen, AstraZeneca, Novartis, and others.
Management board & Supervisory board
| CEO |
| Brett P. Monia |
| Management board |
| Elizabeth L. Hougen, C. Frank Bennett, Onaiza Cadoret-Manier, Joseph T. Baroldi, Richard S. Geary, Patrick R. O’Neil, Eric E. Swayze, Eugene Schneider, Brian Birchler, Michael Yang |
| Supervisory board |
| Joseph Loscalzo, Brett P. Monia, Spencer R. Berthelsen, Allene M. Diaz, Michael Hayden, Joan E. Herman, Joseph Klein, B. Lynne Parshall, Joseph H. Wender |
Company data
| Name: |
Ionis Pharmaceuticals Inc. |
| Address: |
2855 Gazelle Court,Carlsbad, CA 92010 |
| Phone: |
+1-760-931-9200 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.ionispharma.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
99.25% |
| IPO date: |
1991-01-01 |
Investor relations
| Name: |
- |
| IR phone: |
+1-760-603-2331 |
| IR Fax: |
- |
| IR e-mail: |
info@ionisph.com
|
Company calendar
|
CW 19 | 2024-05-07
Interim Report 1st Quarter/3 Months
|
